Efficacy and safety of blinatumomab treatment in adult Korean patients with relapsed/refractory acute lymphoblastic leukemia on behalf of the Korean Society of Hematology ALL Working Party

Sung Hoon Jung, Se Ryeon Lee, Deok Hwan Yang, Seok Lee, Jae Ho Yoon, Hyewon Lee, Soo Mee Bang, Youngil Koh, Silvia Park, Dae Sik Kim, Ho Young Yhim, Sung Hyun Kim, Ji Hyun Lee, Sang Kyun Sohn, Ik Chan Song, Hong ghi Lee, Jung Won Cheong, Yunsuk Choi, Ho Jin Shin

Research output: Contribution to journalArticle

Abstract

Blinatumomab, a bispecific T cell-engaging antibody, has demonstrated efficacy for relapsed or refractory acute lymphoblastic leukemia (ALL). In this study, we evaluated the efficacy and toxicity of blinatumomab in adult Korean patients with relapsed or refractory Philadelphia-negative B cell precursor ALL. A total of 50 patients received blinatumomab treatment between June 2016 and August 2017 in Korea. The median number of prior therapy was one (range, 1–4). Among the 49 evaluable patients, 22 (44.9%) achieved complete response (CR) or CR with incomplete blood count recovery, and 16 of whom subsequently underwent allogenic stem cell transplantation. Although no statistically significant differences were observed, patients with extramedullary disease and poor performance status had lower responses to blinatumomab treatment. In addition, the use of high-dose dexamethasone prior to blinatumomab treatment did not affect the response to blinatumomab. The median event-free survival and overall survival of the responders were 7.5 and 8.1 months, respectively. For non-hematologic toxicities, the most common toxicity was infection. The incidences of severe cytokine release syndrome and neurologic toxicity each was 4%. In conclusion, blinatumomab was an effective and tolerable therapy in adult Korean patients with relapsed or refractory Philadelphia-negative B cell precursor ALL.

Original languageEnglish
JournalAnnals of Hematology
DOIs
Publication statusAccepted/In press - 2018 Jan 1

Fingerprint

Hematology
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Safety
B-Lymphoid Precursor Cells
Therapeutics
Stem Cell Transplantation
Korea
blinatumomab
Dexamethasone
Nervous System
Disease-Free Survival
Cytokines
T-Lymphocytes
Survival
Antibodies
Incidence
Infection

Keywords

  • Acute lymphoblastic leukemia
  • Blinatumomab
  • Predictor

ASJC Scopus subject areas

  • Hematology

Cite this

Efficacy and safety of blinatumomab treatment in adult Korean patients with relapsed/refractory acute lymphoblastic leukemia on behalf of the Korean Society of Hematology ALL Working Party. / Jung, Sung Hoon; Lee, Se Ryeon; Yang, Deok Hwan; Lee, Seok; Yoon, Jae Ho; Lee, Hyewon; Bang, Soo Mee; Koh, Youngil; Park, Silvia; Kim, Dae Sik; Yhim, Ho Young; Kim, Sung Hyun; Lee, Ji Hyun; Sohn, Sang Kyun; Song, Ik Chan; Lee, Hong ghi; Cheong, Jung Won; Choi, Yunsuk; Shin, Ho Jin.

In: Annals of Hematology, 01.01.2018.

Research output: Contribution to journalArticle

Jung, Sung Hoon ; Lee, Se Ryeon ; Yang, Deok Hwan ; Lee, Seok ; Yoon, Jae Ho ; Lee, Hyewon ; Bang, Soo Mee ; Koh, Youngil ; Park, Silvia ; Kim, Dae Sik ; Yhim, Ho Young ; Kim, Sung Hyun ; Lee, Ji Hyun ; Sohn, Sang Kyun ; Song, Ik Chan ; Lee, Hong ghi ; Cheong, Jung Won ; Choi, Yunsuk ; Shin, Ho Jin. / Efficacy and safety of blinatumomab treatment in adult Korean patients with relapsed/refractory acute lymphoblastic leukemia on behalf of the Korean Society of Hematology ALL Working Party. In: Annals of Hematology. 2018.
@article{db2abc326f0e445d96702ca4fd366453,
title = "Efficacy and safety of blinatumomab treatment in adult Korean patients with relapsed/refractory acute lymphoblastic leukemia on behalf of the Korean Society of Hematology ALL Working Party",
abstract = "Blinatumomab, a bispecific T cell-engaging antibody, has demonstrated efficacy for relapsed or refractory acute lymphoblastic leukemia (ALL). In this study, we evaluated the efficacy and toxicity of blinatumomab in adult Korean patients with relapsed or refractory Philadelphia-negative B cell precursor ALL. A total of 50 patients received blinatumomab treatment between June 2016 and August 2017 in Korea. The median number of prior therapy was one (range, 1–4). Among the 49 evaluable patients, 22 (44.9{\%}) achieved complete response (CR) or CR with incomplete blood count recovery, and 16 of whom subsequently underwent allogenic stem cell transplantation. Although no statistically significant differences were observed, patients with extramedullary disease and poor performance status had lower responses to blinatumomab treatment. In addition, the use of high-dose dexamethasone prior to blinatumomab treatment did not affect the response to blinatumomab. The median event-free survival and overall survival of the responders were 7.5 and 8.1 months, respectively. For non-hematologic toxicities, the most common toxicity was infection. The incidences of severe cytokine release syndrome and neurologic toxicity each was 4{\%}. In conclusion, blinatumomab was an effective and tolerable therapy in adult Korean patients with relapsed or refractory Philadelphia-negative B cell precursor ALL.",
keywords = "Acute lymphoblastic leukemia, Blinatumomab, Predictor",
author = "Jung, {Sung Hoon} and Lee, {Se Ryeon} and Yang, {Deok Hwan} and Seok Lee and Yoon, {Jae Ho} and Hyewon Lee and Bang, {Soo Mee} and Youngil Koh and Silvia Park and Kim, {Dae Sik} and Yhim, {Ho Young} and Kim, {Sung Hyun} and Lee, {Ji Hyun} and Sohn, {Sang Kyun} and Song, {Ik Chan} and Lee, {Hong ghi} and Cheong, {Jung Won} and Yunsuk Choi and Shin, {Ho Jin}",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s00277-018-3495-2",
language = "English",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Efficacy and safety of blinatumomab treatment in adult Korean patients with relapsed/refractory acute lymphoblastic leukemia on behalf of the Korean Society of Hematology ALL Working Party

AU - Jung, Sung Hoon

AU - Lee, Se Ryeon

AU - Yang, Deok Hwan

AU - Lee, Seok

AU - Yoon, Jae Ho

AU - Lee, Hyewon

AU - Bang, Soo Mee

AU - Koh, Youngil

AU - Park, Silvia

AU - Kim, Dae Sik

AU - Yhim, Ho Young

AU - Kim, Sung Hyun

AU - Lee, Ji Hyun

AU - Sohn, Sang Kyun

AU - Song, Ik Chan

AU - Lee, Hong ghi

AU - Cheong, Jung Won

AU - Choi, Yunsuk

AU - Shin, Ho Jin

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Blinatumomab, a bispecific T cell-engaging antibody, has demonstrated efficacy for relapsed or refractory acute lymphoblastic leukemia (ALL). In this study, we evaluated the efficacy and toxicity of blinatumomab in adult Korean patients with relapsed or refractory Philadelphia-negative B cell precursor ALL. A total of 50 patients received blinatumomab treatment between June 2016 and August 2017 in Korea. The median number of prior therapy was one (range, 1–4). Among the 49 evaluable patients, 22 (44.9%) achieved complete response (CR) or CR with incomplete blood count recovery, and 16 of whom subsequently underwent allogenic stem cell transplantation. Although no statistically significant differences were observed, patients with extramedullary disease and poor performance status had lower responses to blinatumomab treatment. In addition, the use of high-dose dexamethasone prior to blinatumomab treatment did not affect the response to blinatumomab. The median event-free survival and overall survival of the responders were 7.5 and 8.1 months, respectively. For non-hematologic toxicities, the most common toxicity was infection. The incidences of severe cytokine release syndrome and neurologic toxicity each was 4%. In conclusion, blinatumomab was an effective and tolerable therapy in adult Korean patients with relapsed or refractory Philadelphia-negative B cell precursor ALL.

AB - Blinatumomab, a bispecific T cell-engaging antibody, has demonstrated efficacy for relapsed or refractory acute lymphoblastic leukemia (ALL). In this study, we evaluated the efficacy and toxicity of blinatumomab in adult Korean patients with relapsed or refractory Philadelphia-negative B cell precursor ALL. A total of 50 patients received blinatumomab treatment between June 2016 and August 2017 in Korea. The median number of prior therapy was one (range, 1–4). Among the 49 evaluable patients, 22 (44.9%) achieved complete response (CR) or CR with incomplete blood count recovery, and 16 of whom subsequently underwent allogenic stem cell transplantation. Although no statistically significant differences were observed, patients with extramedullary disease and poor performance status had lower responses to blinatumomab treatment. In addition, the use of high-dose dexamethasone prior to blinatumomab treatment did not affect the response to blinatumomab. The median event-free survival and overall survival of the responders were 7.5 and 8.1 months, respectively. For non-hematologic toxicities, the most common toxicity was infection. The incidences of severe cytokine release syndrome and neurologic toxicity each was 4%. In conclusion, blinatumomab was an effective and tolerable therapy in adult Korean patients with relapsed or refractory Philadelphia-negative B cell precursor ALL.

KW - Acute lymphoblastic leukemia

KW - Blinatumomab

KW - Predictor

UR - http://www.scopus.com/inward/record.url?scp=85053901876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053901876&partnerID=8YFLogxK

U2 - 10.1007/s00277-018-3495-2

DO - 10.1007/s00277-018-3495-2

M3 - Article

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

ER -